- Stocks
- Pharma & Healthcare
- GPT Healthcare
GPT Healthcare share price
NSE: GPTHEALTHPharma & HealthcareMedical Care Facilities
GPT Healthcare at a glance
GPT Healthcare (NSE: GPTHEALTH) closed at ₹135.22 on 22 Oct 2026, down 0.86% on the day. With a market capitalisation of ₹1,110 Cr, it ranks 1402nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 26.3× trailing earnings, against a return on equity of 26.4% in FY22. Over the past year the share price has fallen 8.2%. Its 52-week range is ₹115.00 (27 Mar 2026) to ₹175.00 (31 Jul 2026); the last close is 22.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹126 Cr (+17.8% year on year) and net profit ₹13 Cr (+65.8%), on a standalone basis. Promoters held 65.57% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,110 CrRank 1402 on NSE
- P/E (trailing)
- 26.3×
- Price to book
- 0×FY22
- EPS (TTM)
- ₹5.76to Q1 FY27
- ROE
- 26.4%FY22
- ROCE
- 25.6%FY22
- Debt to equity
- 0.6FY22
- Net profit margin
- 12.3%FY22
- Book value / share
- ₹19.80FY22
- Dividend payout
- 41.4%FY22
- 52-week high
- ₹175.0031 Jul 2026
- 52-week low
- ₹115.0027 Mar 2026
- 1-year return
- −8.2%
- RSI (14-day)
- 28.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.86% | −3.6% | −17.6% | −13.3% | −8.2% |
GPT Healthcare quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹106 Cr | ₹102 Cr | ₹101 Cr | ₹107 Cr | ₹119 Cr | ₹120 Cr | ₹126 Cr | ₹126 Cr |
| Revenue YoY | −2.1% | +5.8% | +2.0% | +9.5% | +12.5% | +17.6% | +24.6% | +17.8% |
| Net profit | ₹15 Cr | ₹12 Cr | ₹13 Cr | ₹8 Cr | ₹11 Cr | ₹9 Cr | ₹15 Cr | ₹13 Cr |
| Net profit YoY | +9.7% | +6.8% | +0.5% | −22.9% | −28.5% | −23.5% | +13.0% | +65.8% |
| Net margin | 14.0% | 12.0% | 12.7% | 7.2% | 8.9% | 7.8% | 11.5% | 10.1% |
| EPS | ₹1.81 | ₹1.49 | ₹1.57 | ₹0.94 | ₹1.29 | ₹1.14 | ₹1.78 | ₹1.55 |
GPT Healthcare financials
| Item | FY21 | FY22 |
|---|---|---|
| Revenue | ₹243 Cr | ₹337 Cr |
| Operating profit | ₹29 Cr | ₹54 Cr |
| Net profit | ₹21 Cr | ₹42 Cr |
| EPS (₹) | ₹3.00 | ₹5.00 |
| Cash from operations | ₹43 Cr | ₹66 Cr |
| Total debt | ₹102 Cr | ₹72 Cr |
| Shareholders' equity | ₹94 Cr | ₹158 Cr |
GPT Healthcare shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 65.57% | 65.57% | 65.57% | 65.57% | 65.57% | 65.57% |
| Foreign institutions | 4.48% | 4.96% | 3.20% | 2.74% | 2.81% | 3.03% |
| Domestic institutions | 11.35% | 9.32% | 6.46% | 6.20% | 6.83% | 6.94% |
| Non-institutions | 18.59% | 20.15% | 24.76% | 25.49% | 24.78% | 24.46% |
GPT Healthcare vs peers
The listed Pharma & Healthcare companies nearest to GPT Healthcare by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AHCLAnlon Healthcare | ₹24.35 | −4.99% | +90.4% | ₹1,294 Cr | 39.9 | — |
| SHALBYShalby | ₹118.16 | −1.53% | −52.1% | ₹1,276 Cr | 36.5 | — |
| GPTHEALTHGPT Healthcare | ₹135.22 | −0.86% | −8.2% | ₹1,110 Cr | 26.3 | — |
| BAJAJHCAREBajaj Healthcare | ₹327.65 | +1.13% | −28.5% | ₹1,103 Cr | 48.6 | — |
| BAFNAPHBafna Pharmaceuticals | ₹451.95 | −2.00% | +195.6% | ₹1,069 Cr | 96.4 | — |
| LINCOLNLincoln Pharmaceuticals | ₹517.50 | +0.10% | −0.9% | ₹1,037 Cr | 11.8 | — |
| SIGACHISigachi Industries | ₹26.24 | −0.08% | −30.3% | ₹1,003 Cr | — | — |
Ask anything about GPT Healthcare
Pivot answers on the live chart with evidence you can check, and tests strategies against GPTHEALTH's own history. Try: “Why has GPTHEALTH moved over the last three months?” · “Backtest a 50-day moving-average crossover on GPTHEALTH over five years” · “Compare GPTHEALTH with AHCL on margins and valuation”
Frequently asked questions about GPT Healthcare
What is the share price of GPT Healthcare today?
GPT Healthcare (NSE: GPTHEALTH) last closed at ₹135.22 on 22 Oct 2026. Its 52-week high is ₹175.00 and its 52-week low is ₹115.00.
What is the market cap of GPT Healthcare?
GPT Healthcare's market capitalisation is ₹1,110 Cr (₹1,110 Cr) at the 22 Oct 2026 close, ranking 1402nd among the NSE companies Pivot tracks.
What is the P/E ratio of GPT Healthcare?
GPT Healthcare trades at a trailing P/E of 26.3. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 39.9.
What is the ROE and ROCE of GPT Healthcare?
Return on equity was 26.4% in FY22 and return on capital employed was 25.6% in FY22 (consolidated figures).
Is GPT Healthcare a debt-free company?
No. GPT Healthcare's debt-to-equity ratio was 0.6 in FY22, with total debt of ₹72 Cr.
What were GPT Healthcare's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), GPT Healthcare reported revenue of ₹126 Cr, +17.8% year on year, and net profit of ₹13 Cr, +65.8% year on year.
How has GPT Healthcare stock performed over the last year?
GPT Healthcare's share price has fallen 8.2% over the past year, −13.3% over three months and −17.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of GPT Healthcare?
As of 30 Jun 2026: promoters 65.57%, foreign institutions 3.03%, domestic institutions 6.94%, non-institutions 24.46%.
Who are GPT Healthcare's competitors?
The listed Pharma & Healthcare companies closest to GPT Healthcare by market cap are Anlon Healthcare, Shalby, Bajaj Healthcare, Bafna Pharmaceuticals, Lincoln Pharmaceuticals and Sigachi Industries.
Is GPT Healthcare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out GPT Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GPTHEALTH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text